ReviewVaccines2015
Optimal Use of Vaccines for Control of Influenza A Virus in Swine.
Review in Vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 122 citations in OpenAlex.
- Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs.NPJ vaccines · 2026Article
- Assessment of pre and postinfection immunity to the hemagglutinin proteins of Influenza A(H1N1)pdm09 and Influenza A(H3N2) in India: a retrospective longitudinal study.Virology journal · 2026Article
- Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies.Journal of virology · 2025Article
- Active surveillance for influenza A virus in swine reveals within-farm reassortment and cocirculation of distinct subtypes and genetic clades.Veterinary microbiology · 2025Article
- Sources and sinks of influenza A virus genomic diversity in swine from 2009 to 2022 in the United States.Journal of virology · 2025Article
- Epitope-optimized vaccine elicits enduring immunity against swine influenza A virus.Nature communications · 2025Article
- Article
- Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.Iranian journal of basic medical sciences · 2025Article
- Swine influenza A replicon particle and live attenuated influenza virus vaccines induce differential systemic and mucosal antibody and T cell responses.Frontiers in veterinary science · 2025Article
- The case for development of a core outcome set (COS) and supplemental reporting guidelines for influenza vaccine challenge trial research in swine.Frontiers in veterinary science · 2025Article
- Effect of stabilizers on the detection of swine influenza A virus (swIAV) in spiked oral fluids over time.Porcine health management · 2024Article
- Immunogenicity and Protective Efficacy of Dose-Sparing Epigraph Vaccine against H3 Swine Influenza A Virus.Vaccines · 2024Article
- Article
- Swine influenza A virus: challenges and novel vaccine strategies.Frontiers in cellular and infection microbiology · 2024Review
- Article
- Article
- Article
- Article
- Veterinarian perceptions and practices in prevention and control of influenza virus in the Midwest United States swine farms.Frontiers in veterinary science · 2023Article
- Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate.Frontiers in veterinary science · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A virus in swine (IAV-S) is one of the most important infectious disease agents of swine in North America. In addition to the economic burden of IAV-S to the swine industry, the zoonotic potential of IAV-S sometimes leads to serious public health concerns. Adjuvanted, inactivated vaccines have been licensed in the United States for over 20 years, and there is also widespread usage of autogenous/custom IAV-S vaccines. Vaccination induces neutralizing antibodies and protection against infection with very similar strains. However, IAV-S strains are so diverse and prone to mutation that these vaccines often have disappointing efficacy in the field. This scientific review was developed to help veterinarians and others to identify the best available IAV-S vaccine for a particular infected herd. We describe key principles of IAV-S structure and replication, protective immunity, currently available vaccines, and vaccine technologies that show promise for the future. We discuss strategies to optimize the use of available IAV-S vaccines, based on information gathered from modern diagnostics and surveillance programs. Improvements in IAV-S immunization strategies, in both the short term and long term, will benefit swine health and productivity and potentially reduce risks to public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.